118 related articles for article (PubMed ID: 21459544)
21. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
Curcio F; Franco T; Topa M; Baldassarre C;
Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
[TBL] [Abstract][Full Text] [Related]
22. [Buprenorphine or methadone for detoxification of young opioid addicts?].
Ebner R; Schreiber W; Zierer C
Psychiatr Prax; 2004 Nov; 31 Suppl 1():S108-10. PubMed ID: 15570521
[TBL] [Abstract][Full Text] [Related]
23. Adherence to Buprenorphine Treatment Guidelines in a Medicaid Program.
Baxter JD; Clark RE; Samnaliev M; Aweh G; O'Connell E
Subst Abus; 2015; 36(2):174-82. PubMed ID: 25706332
[TBL] [Abstract][Full Text] [Related]
24. Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence.
Marsch LA; Stephens MA; Mudric T; Strain EC; Bigelow GE; Johnson RE
Exp Clin Psychopharmacol; 2005 Nov; 13(4):293-302. PubMed ID: 16366759
[TBL] [Abstract][Full Text] [Related]
25. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone.
Seifert J; Metzner C; Paetzold W; Borsutzky M; Passie T; Rollnik J; Wiese B; Emrich HM; Schneider U
Pharmacopsychiatry; 2002 Sep; 35(5):159-64. PubMed ID: 12237786
[TBL] [Abstract][Full Text] [Related]
26. A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees.
Stein BD; Dick AW; Sorbero M; Gordon AJ; Burns RM; Leslie DL; Pacula RL
Subst Abus; 2018; 39(4):419-425. PubMed ID: 29932847
[TBL] [Abstract][Full Text] [Related]
27. Bupreorphine:a new pharmacotherapy for opioid addictions treatment.
Stock C; Shum JH
J Pain Palliat Care Pharmacother; 2004; 18(3):35-54. PubMed ID: 15364630
[TBL] [Abstract][Full Text] [Related]
28. Managing opioid addiction with buprenorphine.
Donaher PA; Welsh C
Am Fam Physician; 2006 May; 73(9):1573-8. PubMed ID: 16719249
[TBL] [Abstract][Full Text] [Related]
29. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
[TBL] [Abstract][Full Text] [Related]
30. Initial strategies for integrating buprenorphine into HIV care settings in the United States.
Sullivan LE; Bruce RD; Haltiwanger D; Lucas GM; Eldred L; Finkelstein R; Fiellin DA
Clin Infect Dis; 2006 Dec; 43 Suppl 4():S191-6. PubMed ID: 17109306
[TBL] [Abstract][Full Text] [Related]
31. Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention.
Burns L; Randall D; Hall WD; Law M; Butler T; Bell J; Degenhardt L
Addiction; 2009 Aug; 104(8):1363-72. PubMed ID: 19549053
[TBL] [Abstract][Full Text] [Related]
32. Opioid plasma concentrations in methadone-and buprenorphine-maintained patients.
Jagsch R; Gombas W; Schindler SD; Eder H; Moody DE; Fischer G
Addict Biol; 2005 Dec; 10(4):365-71. PubMed ID: 16318959
[TBL] [Abstract][Full Text] [Related]
33. Neuropsychological functioning of opiate-dependent patients: a nonrandomized comparison of patients preferring either buprenorphine or methadone maintenance treatment.
Loeber S; Kniest A; Diehl A; Mann K; Croissant B
Am J Drug Alcohol Abuse; 2008; 34(5):584-93. PubMed ID: 18720267
[TBL] [Abstract][Full Text] [Related]
34. Using buprenorphine for outpatient opioid detoxification.
Manlandro JJ
J Am Osteopath Assoc; 2007 Sep; 107(9 Suppl 5):ES11-6. PubMed ID: 17908825
[TBL] [Abstract][Full Text] [Related]
35. [Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex)].
Fhima A; Henrion R; Lowenstein W; Charpak Y
Ann Med Interne (Paris); 2001 Apr; 152 Suppl 3():IS26-36. PubMed ID: 11435992
[TBL] [Abstract][Full Text] [Related]
36. Buprenorphine replacement therapy: a confirmed benefit.
Prescrire Int; 2006 Apr; 15(82):64-70. PubMed ID: 16604748
[TBL] [Abstract][Full Text] [Related]
37. Age related medication for addiction treatment (MAT) use for opioid use disorder among Medicaid-insured patients in New York.
Neighbors CJ; Choi S; Healy S; Yerneni R; Sun T; Shapoval L
Subst Abuse Treat Prev Policy; 2019 Jun; 14(1):28. PubMed ID: 31238952
[TBL] [Abstract][Full Text] [Related]
38. Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone.
Jones HE; Johnson RE; Jasinski DR; Milio L
Drug Alcohol Depend; 2005 Apr; 78(1):33-8. PubMed ID: 15769555
[TBL] [Abstract][Full Text] [Related]
39. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
40. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.
Mintzer IL; Eisenberg M; Terra M; MacVane C; Himmelstein DU; Woolhandler S
Ann Fam Med; 2007; 5(2):146-50. PubMed ID: 17389539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
